Axios @axios
Lecanemab, developed by Japanese drugmaker Eisai and Biogen, is the first treatment shown to delay cognitive decline from Alzheimer's — which affects over six million people in the U.S. https://t.co/tANZ2ULj3u — PolitiTweet.org
Created
Sat Jan 07 17:30:07 +0000 2023
Likes
28
Retweets
5
Source
SocialFlow
View Raw Data
JSON DataView on Twitter
Likely Available
Axios @axios
Lecanemab, developed by Japanese drugmaker Eisai and Biogen, is the first treatment shown to delay cognitive decline from Alzheimer's — which affects over six million people in the U.S. https://t.co/tANZ2ULj3u — PolitiTweet.org